We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Market Dipped But McKesson (MCK) Gained Today
Read MoreHide Full Article
McKesson (MCK - Free Report) ended the recent trading session at $831.21, demonstrating a +1.08% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.43% for the day. Meanwhile, the Dow lost 0.37%, and the Nasdaq, a tech-heavy index, lost 0.94%.
Shares of the prescription drug distributor witnessed a gain of 0.25% over the previous month, beating the performance of the Medical sector with its loss of 2.36%, and underperforming the S&P 500's gain of 0.89%.
The investment community will be paying close attention to the earnings performance of McKesson in its upcoming release. The company is slated to reveal its earnings on February 4, 2026. The company is expected to report EPS of $9.31, up 15.94% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $105.54 billion, up 10.75% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $38.63 per share and revenue of $407.94 billion. These results would represent year-over-year changes of +16.88% and +13.62%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. McKesson is currently sporting a Zacks Rank of #2 (Buy).
With respect to valuation, McKesson is currently being traded at a Forward P/E ratio of 21.29. For comparison, its industry has an average Forward P/E of 17.83, which means McKesson is trading at a premium to the group.
We can additionally observe that MCK currently boasts a PEG ratio of 1.35. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.92.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 84, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why the Market Dipped But McKesson (MCK) Gained Today
McKesson (MCK - Free Report) ended the recent trading session at $831.21, demonstrating a +1.08% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 0.43% for the day. Meanwhile, the Dow lost 0.37%, and the Nasdaq, a tech-heavy index, lost 0.94%.
Shares of the prescription drug distributor witnessed a gain of 0.25% over the previous month, beating the performance of the Medical sector with its loss of 2.36%, and underperforming the S&P 500's gain of 0.89%.
The investment community will be paying close attention to the earnings performance of McKesson in its upcoming release. The company is slated to reveal its earnings on February 4, 2026. The company is expected to report EPS of $9.31, up 15.94% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $105.54 billion, up 10.75% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $38.63 per share and revenue of $407.94 billion. These results would represent year-over-year changes of +16.88% and +13.62%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. McKesson is currently sporting a Zacks Rank of #2 (Buy).
With respect to valuation, McKesson is currently being traded at a Forward P/E ratio of 21.29. For comparison, its industry has an average Forward P/E of 17.83, which means McKesson is trading at a premium to the group.
We can additionally observe that MCK currently boasts a PEG ratio of 1.35. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.92.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 84, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.